Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Key Takeaways Starting dose: 2 mg once weekly for 4 weeks Titration pace: Increase every 4 weeks: 2 4 8 12 mg Maximum dose: 12 mg weekly (Phase 2/3 clinical trial protocol) Total ramp-up: ~16 weeks to reach maximum dose Mechanism: Triple agonist (GLP-1 + GIP + Glucagon), the only triple-agonist in late-stage trials Weight loss: Up to 24.2% at 48 weeks (Phase 2) and 28.7% at 68 weeks (Phase 3 TRIUMPH-4) GLP-3 Retatrutide Dosage Chart Free printable reference chart showing the retatrutide (GLP-3) clinical trial titration schedule from 2 mg to 12 mg weekly
The Drug Product Database shows multiple active DINs for each of the semaglutide and tirzepatide brands, covering the various strengths and pen configurations sold in that market
Who its for May be a fit if you Are exploring provider-guided weight management Want a dual-pathway option for appetite control Have plateaued on a single-pathway GLP-1 Want licensed provider oversight and ongoing support Not appropriate if you Have a personal or family history of medullary thyroid carcinoma or MEN 2 Are pregnant, trying to conceive, or breastfeeding Have a history of pancreatitis or certain GI conditions (discuss with your provider) Are advised against GLP-1 care by your provider Eligibility is always determined by a licensed provider after reviewing your intake
One of the biggest myths is that theyre painful
CAS 137525-51-0 MW 1419.53 g/mol Sequence Not listed Half-life Not listed Formula C62H98N16O22 Purity 99.65% Form Lyophilized powder Class Gastric Pentadecapeptide The dossier
